• RRP and Lipid Metabolism in Hepatic Ischemia–Reperfusion

  2026-10-12

  A preclinical Journal of Ethnopharmacology study links Radix Rehmanniae Praeparata extract with improved hepatic ischemia–reperfusion injury in mice and lipid-stressed hepatocytes, while leaving the active constituents and clinical relevance unresolved.

• Oleic Acid in Hepatic Lipid-Metabolism Research

  2026-10-12

  A 2024 mouse and hepatocyte study reported that Radix Rehmanniae Praeparata extract alleviated hepatic ischemia–reperfusion injury alongside changes in AMPK, mTOR, SCAP–SREBP2, and LXRα signaling. Because the cellular model combined Oleic Acid with palmitic acid and the intervention was a complex botanical extract, the findings support a mechanistic research hypothesis rather than an Oleic Acid-specific or clinically established treatment effect.

• Coil–Bottlebrush Diblocks in Ionic Liquids

  2026-10-10

  Rodriguez, Mahanthappa, and Lodge examine how coil–bottlebrush diblock copolymers self-assemble in alkylimidazolium ionic liquids with systematically varied alkyl-chain lengths. Their central finding is that diverse, sometimes coexisting lyotropic morphologies appear with surprisingly weak dependence on ionic-liquid identity, suggesting a broader materials-design space for network-forming block copolymers.

• Cyclosporin Variants and Mitochondrial Pore Activity

  2026-10-09

  Efimov and colleagues combined NMR spectroscopy, molecular dynamics, and mitochondrial swelling analysis to examine how small structural differences among cyclosporin variants affect mitochondrial permeability transition pore activity. Their results identify a notable contrast: variants B–D showed activity comparable to Cyclosporin A, whereas the more conformationally rigid variant E was inactive in the reported assay range, supporting a relationship between peptide flexibility and biological availability.

• Calcein AM/PI Staining in Cerebral Hemorrhage Research

  2026-10-08

  A source-grounded overview of how Calcein AM/PI fluorescence can contextualize neuronal injury research, using the 2026 Eerdun Wurile cerebral hemorrhage study to compare viability readouts with histology, apoptosis, behavior, and pathway evidence.

• ABT-888 (Veliparib): Interpreting PARP Sensitization

  2026-10-08

  ABT-888 (Veliparib) is a selective PARP1/2 inhibitor used to study DNA repair inhibition and treatment sensitization. This article places its preclinical evidence alongside recent findings on PPP2R2A-linked CHK1 dependence, clarifying what PARP response can—and cannot—show in cancer models.

• ABT-199 and the Next Era of BCL-2 Translation

  2026-10-07

  ABT-199, also known as Venetoclax or GDC-0199, is more than a selective BCL-2 probe: it is a way to test whether mitochondrial apoptotic dependence is causal, measurable, and therapeutically actionable. This thought-leadership article connects selective BCL-2 inhibition with Mcl-1 biology, evidence from glioblastoma models, and translational strategy for hematologic malignancy research.

• Mc-Val-Cit-PABC-PNP Product Overview

  2026-10-07

  Supplier-listed identity and conceptual scope for Mc-Val-Cit-PABC-PNP, with no matched paper evidence available to validate performance or specific applications.

• Auranofin at the Redox–Mechanotransduction Interface

  2026-10-06

  An evidence-graded perspective on Auranofin as a thioredoxin reductase inhibitor connecting redox biology, apoptosis, tumor mechanics, and translational cancer research.

• uPAR–uPA Inhibition in Breast Cancer Metastasis

  2026-10-06

  Mani and colleagues combined direct biophysical binding evidence, cellular invasion assays, pharmacokinetics, and a murine metastasis model to evaluate compound 4 as an inhibitor of the uPAR–uPA interaction. The study supports compound 4 as a mechanistic starting point rather than a clinically validated therapy, with the strongest evidence showing direct uPAR binding, impaired invasive behavior, measurable tumor exposure, and reduced metastatic burden in the reported model.

• ABT-888 (Veliparib): Interpreting DDR Evidence

  2026-10-05

  ABT-888 (Veliparib) is a PARP1/2 inhibitor used to study DNA repair inhibition and treatment sensitization. This evidence-led analysis explains why PARP activity, TP53 status, ATM signaling, and tumor context must be interpreted together rather than treated as universal predictors of response.

• Mc-Val-Cit-PABC-PNP Product Overview

  2026-10-05

  Mc-Val-Cit-PABC-PNP (SKU B1003) is supplier-described as a cathepsin B-cleavable ADC peptide linker. The supplied materials provide catalog specifications but no matched paper evidence, so product-specific performance, mechanisms, and clinical applicability are not independently established here.

• Irinotecan (CPT-11): Evidence and Research Context

  2026-10-04

  Irinotecan, also known as CPT-11, is a topoisomerase I-targeting anticancer prodrug used in colorectal cancer research. This overview distinguishes reported cell and xenograft findings from stronger conclusions, explains conceptual applications, and outlines limitations involving model-specific activation, endpoint comparability, source provenance, and clinical translation.

• Protease Inhibitor Cocktail: Preserving TIE2 Biology

  2026-10-03

  Explore how a Protease Inhibitor Cocktail supports more reliable interpretation of TIE2, extracellular-vesicle, and macrophage angiogenesis studies. This evidence-focused analysis explains the EDTA-free formulation, assay relevance, and limits of protease control.

• Ivermectin: Workflow Design for Mechanistic Research

  2026-10-01

  Build reproducible Ivermectin assays by controlling solvent, exposure, and orthogonal readouts across parasite and exploratory cancer workflows. A 2024 pancreatic cancer study provides a useful model for separating phenotype from mechanism without misclassifying Ivermectin as a validated GSDMC inhibitor.

7991 records 1/533 page Next 12345 下5页 Last page